Background. The epidemiology of human herpesvirus 6 (HHV-6) encephalitis after allogeneic hematopoietic cell transplantation (HCT) and its relationship with HHV-6 reactivation have not been sufficiently characterized.
recipients of allogeneic hematopoietic cell transplantation (HCT), reactivations of HHV-6 are common [2, 3] and related to various post-transplant complications [4] [5] [6] . Most HHV-6 reactivation in the setting of HCT is due to HHV-6B [2, 6] . HHV-6 encephalitis is a serious post-transplant complication that is sporadically caused by HHV-6 reactivation [3, 5, 7, 8] . Mortality rates attributable to this pathology remain high [7, [9] [10] [11] [12] [13] [14] , and even among survivors, many patients display cognitive sequelae [15] .
Despite the poor outcome, the effects of systemic HHV-6 reactivation on the development of HHV-6 encephalitis and the morbidity of HHV-6 encephalitis have not been sufficiently characterized. This makes preventative options difficult to establish. The European Conference on Infections in Leukemia does not recommend antiviral prophylaxis against HHV-6 reactivation because of the low risk of HHV-6 disease and the toxicity of available antiviral drugs [16] . Recently, high incidences of HHV-6 encephalitis (5.7%-8.0%) have consistently been reported from HCT units in Japan [3, 8, 12, 14, 15, 17] . However, these studies have been retrospective, using less-stringent definitions of HHV-6 encephalitis and small populations. Some studies have suggested associations between high-level HHV-6 reactivation and development of central nervous system (CNS) dysfunction, but these associations were evaluated retrospectively [3, 8, 18] . A recent prospective study demonstrated an independent association between HHV-6 reactivation and subsequent delirium [19] . However, determining the proportion of cases with HHV-6 encephalitis is difficult, because cerebrospinal fluid (CSF) was obtained in only a small subset (4 of 19) of patients, and 2 of those 4 patients did not show detectable levels of HHV-6 DNA in CSF [19] .
The present study investigated the epidemiology and morbidity of HHV-6 encephalitis in allogeneic HCT recipients, focusing on the relationship between plasma HHV-6 load and development of HHV-6 encephalitis using data on prospectively monitored HHV-6 load.
PATIENTS AND METHODS

Study Design and Patients
This prospective, multicenter trial was approved by the ethics committees of each contributing center. All patients who underwent allogeneic HCT between July 2010 and December 2011 were registered to this study. Written informed consent was obtained from all patients in accordance with the Declaration of Helsinki. The primary endpoint of the study was HHV-6 encephalitis episodes. The observation period for assessing HHV-6 reactivation and CNS dysfunction was from 1 to 70 days after transplantation.
Patient Care
Transplantation regimens, including selection of stem cell source, conditioning regimens, antiviral prophylaxis, and prophylaxis of acute graft-versus-host disease (GVHD) were determined according to the protocol of each institute and participation in this study had no effect on these clinical decisions. All patients were administered oral acyclovir at 600-1000 mg/day from day 7 to day 35 to prevent infection with herpes simplex virus. Cytomegalovirus prevention consisted of weekly antigenemia surveillance and preemptive therapy with ganciclovir. The decision to administer antivirals prophylactically to prevent HHV-6 encephalitis was made at the discretion of the attending physician. If highlevel HHV-6 DNA (≥10 4 copies/mL plasma) was confirmed by HHV-6 monitoring in this study, physicians were able to start administering antivirals against HHV-6 reactivation.
Specimen Collection
After transplantation, EDTA-treated peripheral blood was collected prospectively and basically twice a week until 70 days after transplantation or discharge. Within 3 hours after sampling, separation of plasma from whole blood was performed by centrifugation (1500 × g for 10 minutes) at each institute. Plasma samples were immediately frozen at −30°C, and sent to Oita University Hospital on the day of collection in a frozen state for HHV-6 DNA testing. Shipping time was 2-3 days in most cases.
HHV-6 DNA Quantification
HHV-6 DNA copy numbers in plasma samples were measured using real-time polymerase chain reaction (PCR) methods, as described elsewhere [3] . This PCR system detects both HHV-6A and HHV-6B. Real-time PCR was performed basically twice a week (Monday and Thursday) at Oita University Hospital and HHV-6 DNA loads were reported to each institute on the day of quantification.
Definitions
Disease phase was evaluated against patients with hematological neoplasms. Early stage was defined as: acute leukemia in first to second remission; chronic myeloid leukemia in first chronic phase; or myelodysplastic syndrome classified as refractory anemia without excess of blasts. All others were considered non-early stage. Myeloablative conditioning (MAC) regimens were defined as: total body irradiation (TBI) with 1 fraction of >5 Gy or fractionated doses of >8 Gy, busulfan doses >9 mg/kg, or melphalan doses >140 mg/m 2 . Reduced-intensity conditioning (RIC) regimens were defined as follows: TBI doses ≤5 Gy in a single fraction; busulfan doses ≤9 mg/kg; melphalan doses ≤140 mg/m 2 ; and fludarabine-based regimens without myeloablative doses of TBI, busulfan, or melphalan [20] . Diagnosis and grading of acute GVHD were based on the clinical criteria described elsewhere [21] . Steroid treatment was defined as treatment with ≥0.5 mg/kg of prednisolone or methylprednisolone for >1 week. HHV-6 reactivation was defined as detection of HHV-6 DNA in plasma at any level. High-level HHV-6 reactivation was defined as a plasma HHV-6 DNA ≥10 4 copies/ mL. This was set based on our findings of retrospective studies that the threshold level for the development of HHV-6 encephalitis was 10 4 copies/mL plasma under our real-time PCR assay [3, 8] . In addition, this level was close to the median maximum plasma HHV-6 load among patients with positive results in the present study (11 387 copies/mL). CNS dysfunction was defined as the presence of lethargy or apathy, disorientation regarding time of place, personality change, systemic convulsions, loss of consciousness, or memory loss that persisted for >24 hours. HHV-6 encephalitis was defined as the presence of CNS dysfunction, a positive PCR result for HHV-6 DNA in CSF, and the absence of other identified causes of CNS dysfunction.
Statistical Analyses
All censored criteria were calculated from the time of transplantation. Probabilities of the first incidence of HHV-6 reactivation, high-level HHV-6 reactivation, CNS dysfunction, and HHV-6 encephalitis were calculated based on cumulative incidence curves. Competing events were discontinuance of HHV-6 DNA monitoring before the 10th week after transplantation for HHV-6 reactivation and high-level HHV-6 reactivation, death without experiencing the events for CNS dysfunction for CNS dysfunction, and death without HHV-6 encephalitis for HHV-6 encephalitis. Groups were compared using Grey test. The Fine-Grey proportional hazards model was used to evaluate the effects of confounding variables on HHV-6 reactivation.
Comparisons of proportion for HHV-6 encephalitis between groups were made using Fisher exact test. All statistical tests were 2-sided and performed using a 5% level of significance. Statistical analyses were carried out using EZR (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (R Foundation for Statistical Computing, ver. 2.13.0) [22] .
RESULTS
Patient Characteristics
Between July 2010 and December 2011, a total of 260 patients were preliminarily enrolled in this study. Among these, 30 patients were excluded from analysis, because of insufficient sampling (<3 samples during the first 21 days after transplantation, n = 8), registration after receiving transplantation (n = 3), results consistent with chromosomally integrated HHV-6 (ciHHV-6; persistent levels ≥100 copies/mL in ≥80% of subsequent plasma samples after day 14 after transplantation [19] , ciHHV-6 in recipient, n = 2; ciHHV-6 in donor, n = 1; origin undetermined, n = 1), or receiving second or more allogeneic HCT (n = 15). Kinetics of plasma HHV-6 DNA in patients with presumed ciHHV-6 is shown in the Supplementary Figure. None of the 4 patients with presumed ciHHV-6 developed encephalopathy. Characteristics of the 230 patients who were included in the analyses are summarized in Table 1 . Eighty-three patients (36.1%) received antiviral agents active against HHV-6 (ganciclovir, valganciclovir, or foscarnet) within 30 days after transplantation. Among these, 27 patients (umbilical cord blood transplantation [UCBT] recipients, n = 23; non-UCBT recipients, n = 4) received these antivirals to prevent development of HHV-6 encephalitis, and 18 patients received them in response to confirmation of highlevel HHV-6 reactivation. The remaining patients received these antivirals against cytomegalovirus reactivation.
Patient Samples
In total, 3537 samples were examined using real-time PCR. Blood-sample collection was started at a median of 3 days after transplantation (range, 1-15 days) and lasted at a median of 59.5 days after transplantation (range, 12-70 days). Collection intervals between samples were as follows: 1-2 days, n = 176; 3-4 days, n = 2843; 5-6 days, n = 207; 7-8 days, n = 45; 9-10 days, n = 17; 11-12 days, n = 11; and 13-15 days, n = 8. The median number of blood samples per patient was 16 (range, 3-21).
HHV-6 Reactivation
HHV-6 DNA was most frequently apparent in plasma at 15-21 days (3rd week) after HCT ( Figure 1A and 1B). Cumulative incidences for the first detection of positive HHV-6 DNA, HHV-6 DNA ≥10 4 copies/mL plasma, and HHV-6 DNA ≥10 5 copies/mL plasma at 70 days after HCT were 72.2%, 37.0%, and 10.0%, respectively ( Figure 1C ). Median maximum plasma HHV-6 load among patients with positive results was 11 387 copies/mL (range, 70.5-4 991 563.5 copies/mL). Although plasma HHV-6 DNA level exceeded 1 000 000 copies/mL in one patient, that patient was not considered as having ciHHV-6 because the HHV-6 DNA load eventually decreased to an undetectable level.
Risk Factors for HHV-6 Reactivation
By univariate analysis, UCBT, MAC, conditioning without antithymocyte globulin (ATG), GVHD ≥grade 2, and steroid treatment after HCT were associated with increased risk of HHV-6 reactivation, while male sex, UCBT, MAC, conditioning without ATG, and GVHD ≥ grade 2 were associated with high-level HHV-6 reactivation ( Table 2 ). Figure 2A and 2B show the cumulative incidence curves for first HHV-6 reactivation and high-level HHV-6 reactivation in recipients of UCBT and non-UCBT. Multivariate analysis for the pretransplant parameter revealed MAC and UCBT as risk factors for HHV-6 reactivation and MAC, male sex, and UCBT as risk factors for high-level HHV-6 reactivation (Table 3) .
CNS Dysfunction
During the observation period 70 days after HCT, 33 of 230 patients (14.3%) developed CNS dysfunction. Etiologies of CNS dysfunctions were HHV-6 encephalitis (n = 7), cerebral bleeding (n = 3), posterior reversible encephalopathy syndrome (n = 3), drug-induced encephalopathy (n = 3, due to opioid or major tranquilizer), uremic encephalopathy (n = 1), CNS relapse (n = 1), and unknown (n = 15). Cumulative incidences of CNS dysfunction and HHV-6 encephalitis at 70 days after HCT were 14.4% and 3.0%, respectively. Characteristics of patients who developed CNS dysfunctions are summarized in Table 4 . We grouped these patients with CNS dysfunction into 2 groups: Cases 1-13 as the high-plasma HHV-6 DNA group (HHV-6 DNA ≥10 4 copies/mL plasma); and cases 14-33 as the low-or negative plasma HHV-6 DNA group (HHV-6 DNA <10 4 copies/mL plasma). This was set based on the findings from the present study that median maximum plasma HHV-6 load among patients with positive results was 11 387 copies/mL. Among patients in whom HHV-6 DNA in CSF was evaluated around the time of developing CNS dysfunction, HHV-6 DNA was demonstrated in all of the 7 patients with high-plasma HHV-6 DNA and none of the 7 patients with low-or negative plasma HHV-6 DNA. Diagnosis of HHV-6 encephalitis was therefore made based on positive HHV-6 DNA in CSF in 7 of 13 patients (53.8%) in the high-plasma HHV-6 DNA group, and none of the 20 patients (0%) in the low-or negative plasma HHV-6 DNA group (P = .0004). Detailed findings for the 7 patients diagnosed with HHV-6 encephalitis are shown in Table 5 . In 5 of 6 patients in the high-plasma HHV-6 DNA group who did not receive CSF examination, the etiology of CNS dysfunction has not been determined. Abbreviations: ATG, antithymocyte globulin; BM, bone marrow; CB, cord blood; CI, cumulative incidence; GVHD, graft-versus-host disease; HCT, hematopoietic cell transplantation; HHV-6, human herpesvirus 6; HLA, human leukocyte antigen; MAC, myeloablative conditioning; PBSC, peripheral blood stem cells; RIC, reduced-intensity conditioning. a Grey test.
b Eight patients with aplastic anemia were not included.
c Thirteen patients were not included (8 patients with aplastic anemia, 4 patients with acute leukemias of ambiguous lineage, and 1 patient with Langerhans cell histiocytosis).
Risk Factors for HHV-6 Encephalitis
UCBT and HCT from human leukocyte antigen (HLA)-mismatched donors were significantly associated with development of HHV-6 encephalitis by univariate analysis. Figure 2C shows the cumulative incidence curve of HHV-6 encephalitis in recipients of UCBT and non-UCBT. Multivariate analysis for the risk factors of HHV-6 encephalitis was not performed, because the number of patients who developed HHV-6 encephalitis was small and HLA mismatch is associated with UCBT. HLA allelic mismatch was not significantly associated with the incidence of HHV-6 encephalitis among recipients of UCBT (P = .50) and recipients of non-UCBT (P = .12). Figure 3 shows the kinetics of HHV-6 DNA in plasma and CSF in patients who developed HHV-6 encephalitis. CNS dysfunction developed concomitant to peak HHV-6 DNA. Median maximum plasma HHV-6 load among patients who developed HHV-6 encephalitis was 121 436 copies/mL (range, 21 656-433 639 copies/mL). Median duration between first detection of positive plasma HHV-6 DNA and development of CNS dysfunction was 4 days (range, 1-14 days).
Kinetics of Plasma HHV-6 DNA in Patients Who Developed HHV-6 Encephalitis
Association Between Plasma HHV-6 DNA Load and HHV-6 Encephalitis
Associations between maximum plasma HHV-6 DNA load in each of the 230 patients and development of HHV-6 encephalitis were evaluated. Incidences of HHV-6 encephalitis were 0% and 8.1% among patients with peak plasma HHV-6 DNA <10 4 copies/mL (n = 144) and ≥10 4 copies/mL (n = 86), respectively (P = .0009). Among patients displaying ≥10 5 HHV-6 DNA copies/mL plasma (n = 25), HHV-6 encephalitis occurred in 4 patients, and the incidence was 16%. For identifying HHV-6 encephalitis, plasma HHV-6 DNA ≥10 4 copies/mL offered 100% sensitivity and 64.6% specificity, and plasma HHV-6 DNA ≥10 5 copies/mL offered 57.1% sensitivity and 90.6% specificity.
DISCUSSION
This large-scale, prospective, multicenter study evaluated the epidemiology and morbidity of HHV-6 reactivation and HHV-6 encephalitis and analyzed these associations. Although HHV-6 reactivation was common after allogeneic HCT, HHV-6 encephalitis sporadically developed at the time of HHV-6 Abbreviations: C, cord blood; CNS, central nervous system; CSF, cerebrospinal fluid; HHV-6, human herpesvirus 6; ND, not done; NI, not informative; PRES, posterior reversible encephalopathy syndrome; R, bone marrow of peripheral blood stem cell from related donor; TMA, thrombotic microangiopathy; U, bone marrow from unrelated donor. a No. of days between transplantation and onset of CNS dysfunction.
b Peak HHV-6 DNA load in plasma between 7 days before and 7 days after onset of CNS dysfunction.
c Interpretation of physician. reactivation if the reactivation level was high. Our data provide evidence of the effect of HHV-6 reactivation on the development of HHV-6 encephalitis after allogeneic HCT. The significance of HHV-6 reactivation detected by blood HHV-6 DNA for the development of HHV-6 encephalitis has not been sufficiently determined. Some epidemiological studies have not found a significant relationship between HHV-6 reactivation and CNS diseases [23, 24] . A recent, well-designed, large prospective study [19] identified HHV-6 reactivation as a predictor of CNS dysfunction. However, the etiology of CNS dysfunction was not sufficiently determined because most patients did not undergo CSF examination. The present study required the detection of HHV-6 DNA in CSF for diagnosis of HHV-6 encephalitis and showed that higher levels of plasma HHV-6 DNA were associated with increased risk of developing HHV-6 encephalitis.
HHV-6 Encephalitis in
A high incidence of HHV-6 encephalitis has continuously been reported from several Japanese groups [3, 8, 12, 14, 15, 17] . However, epidemiological evidence of incidence and risk factors of HHV-6 encephalitis is limited, due to a less-stringent definition of HHV-6 encephalitis, retrospective design, and small study population. In the present prospective study, 7 of 230 patients developed HHV-6 encephalitis. Selection of cord blood as a stem cell source represents a significant risk factor for the development of HHV-6 encephalitis. The high incidence of HHV-6 encephalitis in patients undergoing UCBT is likely associated with the higher frequency and degree of HHV-6 reactivation.
Two recent studies have also shown higher incidences of HHV-6 encephalitis after UCBT. In a single-center retrospective study, the incidence of HHV-6 encephalitis was 9.9% after UCBT and 0.7% after adult-donor HCT [13] . In a literature review, incidence of HHV-6 encephalitis was 8.3% after UCBT and 0.5% after adult-donor HCT [25] . Prospective evaluation in this study also showed a similar incidence. The high incidence of HHV-6 encephalitis in UCBT recipients may be associated with the amount and function of T cells, as cord blood transplants contain only a small number of T cells that are immunologically immature in the absence of HHV-6-specific T cells.
In patients who developed HHV-6 encephalitis, median duration between first detection of plasma HHV-6 DNA and development of CNS dysfunction was only 4 days. This indicates that monitoring plasma HHV-6 DNA is not useful for predicting the development of HHV-6 encephalitis. In patients showing distinctive CNS symptoms, however, high levels of plasma HHV-6 DNA are suggestive of HHV-6 encephalitis and may allow for earlier initiation of treatment. In fact, all patients who developed HHV-6 encephalitis in this study were able to receive antivirals against HHV-6 early based on the plasma HHV-6 DNA results. No patients with HHV-6 encephalitis died as a direct result of the encephalitis, and 5 of the 7 patients did not retain neuropsychological disorders.
Among patients who developed CNS dysfunction concomitant with high-plasma HHV-6 DNA levels, CSF was obtained from 7 of 13 patients. HHV-6 DNA was demonstrated in all 7 patients. In another 6 patients for whom CSF was not obtained, etiologies of 5 patients were not determined. These proportions suggest that CNS dysfunction in some of these patients may also be caused by HHV-6. Actually, lumbar puncture is sometimes difficult to perform for patients who developed CNS dysfunction in the early phase of transplantation due to severe Figure 3 . Kinetics of human herpesvirus 6 (HHV-6) DNA in 7 patients who developed HHV-6 encephalitis. Abbreviations: AML, acute myeloid leukemia; HHV-6, human herpesvirus 6; MF, myelofibrosis; NHL, non-Hodgkin lymphoma; rBMT, related bone marrow transplantation; uBMT, unrelated bone marrow transplantation; UCBT, umbilical cord blood transplantation.
thrombocytopenia or experienced rapid exacerbation of general condition. One practical management for such patients may be that HHV-6 encephalitis should be considered as a cause of CNS dysfunction if blood HHV-6 DNA is high at the time of developing CNS dysfunction.
Several limitations must be considered in the interpretation of the present results. One is the diagnosis of CNS dysfunction. This study recommended the demonstration of HHV-6 DNA as a criterion for diagnosing HHV-6 encephalitis. CSF was not obtained from 8 of the 15 patients with unknown etiology of CNS dysfunction. This raises the possibility of underestimating the frequency of HHV-6 encephalitis. Another limitation is that our PCR system cannot distinguish between HHV-6A and HHV-6B. Currently, the methods for real-time PCR to evaluate HHV-6 DNA loads have not been standardized [26] . We used one of the recommended PCR assays that provided results closest to the expected value [26] , although the assay detects both HHV-6A and HHV-6B. We have previously performed DNA sequencing of amplified viral DNA in samples containing high-level HHV-6 DNA to distinguish between HHV-6A and HHV-6B. As a result, more than 99% of samples contained HHV-6B only. In this study, DNA sequencing to differentiate HHV-6A from HHV-6B was not performed to allow processing of a large quantity of specimens.
In conclusion, the present results demonstrate an association between high-level HHV-6 reactivation and development of HHV-6 encephalitis. UCBT is a significant risk factor for both HHV-6 reactivation and HHV-6 encephalitis. Monitoring of plasma HHV-6 DNA is useful to identify HHV-6 encephalitis in patients with CNS dysfunction. Based on the results, we propose a clinical trial of prophylactic antiviral intervention in UCBT recipients.
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